Physician profile
Stuart Alan Lewis
NPI 1700874765
$7,630.50
in general payments reported to CMS, 2019-2025
37 companies · $1,097 in 2025
The $1,097 reported for 2025 was more than what 79% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $658 · 2020: $411 · 2021: $902 · 2022: $1,734 · 2023: $1,707 · 2024: $1,121 · 2025: $1,097.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,900 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,899.96 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,439.31 | 2022-2025 | |
| Alcon Vision LLC | $1,289.21 | 2021-2025 | Rocklatan, Rhopressa, Clareon |
| Allergan, INC. | $455.58 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $433.81 | 2022-2025 | Xiidra, Ic-8 Apthera Iol, Envista Mx60 Iol |
| Johnson & Johnson Surgical Vision, INC. | $384.92 | 2019-2024 | Tecnis Simplicity |
| Sight Sciences, INC. | $369.84 | 2019-2023 | Tearcare System |
| Aerie Pharmaceuticals, INC. | $357.27 | 2019-2021 | |
| Rxsight INC | $280.77 | 2021-2024 | Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens, Rxsight Injector Handpiece |
| Tarsus Pharmaceuticals, INC. | $255.98 | 2024-2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $224.10 | 2019-2023 | |
| Glaukos Corporation | $210.62 | 2019-2025 | Photrexa Viscous and Photrexa |
| Sun Pharmaceutical Industries INC. | $186.06 | 2019-2025 | Cequa |
| New World Medical,INC. | $181.68 | 2023 | |
| Thea Pharma INC. | $179.91 | 2022-2025 | Iyuzeh |
| Microsurgical Technology, INC. | $154.06 | 2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $142.27 | 2021-2025 | |
| Avedro INC. | $125.00 | 2019 | |
| Coopervision INC. | $120.68 | 2019-2023 | Myday Contact Lens |
| Dompe US, INC. | $110.03 | 2021-2025 | Oxervate |
| Akorn Operating Company LLC | $89.86 | 2021 | |
| Abb Con-Cise Optical Group LLC | $80.83 | 2025 | Contact Lens |
| Oyster Point Pharma, INC. | $79.08 | 2022-2025 | Tyrvaya, Ryzumvi |
| Harrow Eye, LLC | $68.55 | 2024-2025 | Vevye |
| Kala Pharmaceuticals, INC. | $56.98 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $53.42 | 2022-2023 | Acthar |
| Horizon Therapeutics Plc | $45.21 | 2023 | Tepezza |
| Carl Zeiss Meditec Ag | $38.80 | 2020 | |
| Ocular Therapeutix, INC. | $33.60 | 2023 | Dextenza |
| Mallinckrodt Enterprises LLC | $23.93 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $23.38 | 2020 | |
| Astellas Pharma US INC | $23.00 | 2024 | Izervay |
| Amgen INC. | $22.17 | 2024 | Tepezza |
| Akorn, INC. | $20.89 | 2019 | |
| Shire North American Group INC | $20.03 | 2019 | |
| Carl Zeiss Meditec USA, INC. | $18.82 | 2023 | |
| Johnson & Johnson Vision Care, INC. | $15.69 | 2025 | |
| Optos, INC. | $15.16 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stuart Lewis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.